Microfabricated Otto chip device for surface plasmon resonance based optical sensing

Surface plasmon resonance (SPR) based sensors are usually designed using the Kretschmann prism coupling configuration in which an input beam couples with a surface plasmon through a thin metal film. This is generally preferred by sensor developers for building planar devices instead of the Otto prism coupling configuration, which, for efficient coupling, requires the metal surface to be maintained at a distance on the order of the wavelength from the input prism surface. In this paper, we report on the microfabrication and characterization of an Otto chip device, which is suitable for applications of the SPR effect in gas sensing and biosensing

Inkjet-Printed Silver CPW with Narrow Gap

Inkjet-printed silver coplanar waveguide on a glass substrate with narrow gap is firstly realized by using a selective surface treatment. The measured gap between signal and ground is 16.7 mm. Insertion loss is measured to be 2.04 dB/cm and 4.40 dB/cm at 10 GHz and 40 GHz, respectively

DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

Mitotic cell division increases tumour mutation burden and copy number load, predictive markers of the clinical benefit of immunotherapy. Cell division correlates also with genomic demethylation involving methylation loss in late-replicating partial methylation domains. Here we find that immunomodulatory pathway genes are concentrated in these domains and transcriptionally repressed in demethylated tumours with CpG island promoter hypermethylation. Global methylation loss correlated with immune evasion signatures independently of mutation burden and aneuploidy. Methylome data of our cohort (n = 60) and a published cohort (n = 81) in lung cancer and a melanoma cohort (n = 40) consistently demonstrated that genomic methylation alterations counteract the contribution of high mutation burden and increase immunotherapeutic resistance. Higher predictive power was observed for methylation loss than mutation burden. We also found that genomic hypomethylation correlates with the immune escape signatures of aneuploid tumours. Hence, DNA methylation alterations implicate epigenetic modulation in precision immunotherapy

RF characteristics of SU-8 and quartz particle composite dielectric for Terahertz applications

An SU-8 and quartz particle composite dielectric layer was fabricated and measured from 0.9 to 1.0 THz. It is well known that SU-8 attenuates the signal due to its inherent high loss if used as a dielectric [1,2]. In this paper we report the possibility of lowering the loss of plain SU-8 by adding quartz particles with a diameter of 1 μm for high packing density. The real permittivity of the fabricated dielectric layer increases and loss tangent decreases according to the increase of quartz particles mass fraction in the range from 0.9 to 1.0 THz. Higher quartz particle mass fraction has a great potential to lower the losses of plain SU-8 for Terahertz applications

A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)

We aimed to evaluate the efficacy of dual inhibition of epidermal growth factor receptor (EGFR) with nimotuzumab (EGFR monoclonal antibody) plus gefitinib (EGFR-tyrosine kinase inhibitor) in advanced non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. An open label, randomized, phase II trial was conducted at 6 centers; 160 patients were randomized (1:1) to either gefitinib alone or nimotuzumab (200 mg, i. v. weekly) plus gefitinib (250 mg p. o. daily) until disease progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS) at 3 months. Of the total 160 enrolled patients, 155 (77: gefitinib, 78: nimotuzumab plus gefitinib) received at least one dose and could be evaluated for efficacy and toxicity. The majority had adenocarcinoma (65.2%) and ECOG performance status of 0 to 1 (83.5%). The median follow-up was 22.1 months, and the PFS rate at 3 months was 48.1% in gefitinib and 37.2% in nimotuzumab plus gefitinib (P = not significant, NS). The median PFS and OS were 2.8 and 13.2 months in gefitinib and 2.0 and 14.0 months in nimotuzumab plus gefitinib. Combined treatment was not associated with superior PFS to gefitinib alone in patients with EGFR mutation (13.5 vs. 10.2 months in gefitinib alone, P=NS) or those with wild-type EGFR (0.9 vs. 2.0 months in gefitinib alone, P=NS). Combined treatment did not increase EGFR inhibition-related adverse events with manageable toxicities. The dual inhibition of EGFR with nimotuzumab plus gefitinib was not associated with better outcomes than gefitinib alone as a second-line treatment of advanced NSCLC (NCT01498562).

Congenital Angiodysplasia in a Woman Presenting with Idiopathic Jejunal Varicosis on Angiography

Angiography is a useful diagnostic tool in cases with massive gastrointestinal bleeding such as angiodysplasia and varicosis when endoscopy is not available. Angiodysplasia and varicosis have distinguishable characteristic features on angiography, such as the presence of a nidus, visible late-draining veins, and the typical vascular tuft. We recently treated a rare case of congenital angiodysplasia without the characteristic angiodysplasia features on angiography. Instead, the patient presented with a very rare case of idiopathic jejunal varicosis. A 42-year-old woman visited the emergency room with the chief complaint of melena for three days and a hemoglobin level of 5.9 g/dL. An abdominal CT angiogram showed varicosis at the jejunal mesentery. Angiography of the superior and inferior mesenteric arteries showed tortuous and dilated jejunal and ileal branches during the venous phase, suggesting a vascular malformation such as varicosis of the jejunum. Surgical exploration with intraoperative endoscopy revealed diffuse engorged veins and a 1.0-cm-diameter superficial ulcer covered with a blood clot that was 70 cm from the ligament of Treitz. A 100-cm segment of jejunum was resected. Histological examination revealed that the lesion was angiodysplasia, not varicosis. The final diagnosis was congenital angiodysplasia

Evaluation of Degradation in Nanofilled Adhesive Resins Using Quantitative Light-Induced Fluorescence

The aim of this study was to evaluate degradation in commercial dental nanofilled adhesive resins using quantitative light-induced fluorescence (QLF). Three adhesives were selected: D/E resin (DR), Single Bond Plus (SB), and G-Bond (GB). The adhesives were mixed with porphyrin for the QLF analysis. Specimens were prepared by dispensing blended adhesives into a flexible mold and polymerizing. Then, the QLF analysis of the specimens was done and the porphyrin values (Simple Plaque Score and ΔR) were measured. After thermocycling of the specimens (5000 cycles, 5 to 55°C) for the degradation, the specimens were assayed by QLF again. The porphyrin values were analyzed using paired t-test at a 95% confidence level. A significant reduction in SPS was observed in all groups after thermocycling. The ΔR significantly decreased after thermocycling except area ΔR30 of SB group. Overall, porphyrin values decreased after thermocycling which indicates that the degradation of the adhesive resins may be measured by the change of porphyrin value. The QLF method could be used to evaluate the degradation of adhesive resin

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection of Patients for Maintenance Therapy

BackgroundProspective studies have implied that maintenance therapy for non-small cell lung cancer (NSCLC) has its effect by giving active drugs earlier to patients who otherwise die without receiving second-line therapy. The purpose of this study was to select patients with NSCLC who could most benefit from maintenance therapy, by evaluating which patients would be less likely to receive second-line therapy.MethodsClinicopathologic data of patients with advanced NSCLC who received four cycles of first-line chemotherapy followed by time-off therapy and eventual disease progression or death were reviewed retrospectively. Patients were grouped into ones with first-line therapy only or ones with more than first-line therapy. Clinical characteristics between the two groups were compared.ResultsA total of 271 patients were eligible for analysis, and 39 patients (14.4%) received only first-line therapy. Patients significantly more likely to receive only first-line therapy had performance status of two or three after first-line therapy, large volume of initial target lesions (sum of long diameters ≥70 mm), or smaller decrease in target lesions (decrease <20%) after first-line therapy. Median overall survival of the 143 patients (52.8%) with at least one of these characteristics (16.3 months) was significantly shorter than that of patients without any of these characteristics (23.5 months, p = 0.007).ConclusionMaintenance therapy may be of greater benefit to patients with NSCLC who have clinical characteristics including poor performance status after first-line therapy, large initial target lesions, or smaller decrease in target lesions after first-line therapy

Recent Trends and Considerations for High Speed Data in Chips and System Interconnects

This paper discusses key issues related to the design of large processing volume chip architectures and high speed system interconnects. Design methodologies and techniques are discussed, where recent trends and considerations are highlighted